文献速递妇科

免疫检查点抑制剂联合化疗用于原发性晚期错配修复缺陷子宫内膜癌的成本效果分析

Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
PubMed 文献 · Gynecol Oncol · 2023-11-16

本研究建立马尔可夫模型纳入6600例原发性晚期错配修复缺陷子宫内膜癌患者,比较帕博利珠单抗联合紫杉醇卡铂(PEM-TC)、度伐利尤单抗联合TC(DOS-TC)与单纯TC的成本效果。以10万美元/QALY为支付意愿阈值,TC相对于PEM-TC和DOS-TC均具成本效果。帕博利珠单抗200 mg价格降至4361美元时PEM-TC具成本效果。

要点

  • 以10万美元/QALY为阈值,单纯TC相对于PEM-TC(ICER 377718美元/QALY)和DOS-TC(ICER 401859美元/QALY)均具成本效果。
  • 帕博利珠单抗200 mg成本降至4361美元(降幅61%)时,PEM-TC具成本效果。
  • 在30万美元/QALY阈值下PEM-TC被选中的比例为16.5%,在10万至20万美元/QALY阈值范围内低于1%。

核心结论

  • 当帕博利珠单抗成本大幅下降时,PEM-TC对原发性晚期MMRd子宫内膜癌可具成本效果。

研究设计与样本

  • 马尔可夫模型研究,纳入6600例原发性晚期MMRd子宫内膜癌患者,模拟PEM-TC、DOS-TC与TC三种治疗策略的结局。
  • 模型概率、成本和健康效用值基于已发表文献的假设得出,效果指标为获得的质量调整生命年(QALY),主要结局为增量成本效果比(ICER)。

主要发现

  • TC为成本最低策略,PEM-TC为最有效策略。
  • 以10万美元/QALY的支付意愿阈值,TC相对于PEM-TC具成本效果,ICER为377718美元/QALY。
  • DOS-TC呈绝对劣势,ICER为401859美元/QALY。
  • 帕博利珠单抗200 mg成本降至4361美元(降幅61%)时,PEM-TC具成本效果。
  • 在30万美元/QALY阈值下PEM-TC被选中的比例为16.5%,在10万至20万美元/QALY阈值范围内低于1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The addition of immune checkpoint inhibitors (ICIs), pembrolizumab or dostarlimab, to paclitaxel and carboplatin (TC) has shown better response rates and survival outcomes for patients with primary advanced mismatch repair-deficient (MMRd) endometrial cancer (EC) in NRG-GY018 and RUBY, respectively. Nonetheless, the high cost of ICIs remains a major concern when implementing this strategy in the real world. This study aimed to determine the cost-effectiveness of pembrolizumab and dostarlimab with chemotherapy compared to TC for primary advanced MMRd EC. METHODS: We developed a Markov model including 6600 patients with primary advanced MMRd EC to simulate treatment outcomes. The initial decision points in the model were treatment with pembrolizumab with TC (PEM-TC), dostarlimab with TC (DOS-TC), and TC. Model probabilities, costs, and health utility values were derived with assumptions from published literature. Effectiveness was determined as average quality-adjusted life years (QALYs) gained. The primary outcome was the incremental cost-effectiveness ratio (ICER). RESULTS: TC was the least costly strategy, whereas PEM-TC was the most effective strategy for primary advanced MMRd EC. TC was cost-effective based on a willingness-to-pay (WTP) threshold of $100,000/QALY compared with PEM-TC (ICER, $377,718/QALY), and DOS-TC exhibited absolute dominance (ICER, $401,859/QALY). PEM-TC was cost-effective when the cost of pembrolizumab 200 mg was reduced to $4361 (61% reduction). PEM-TC was selected in 16.5% with a WTP threshold of $300,000/QALY, but in <1% with a WTP threshold range of $100,000-200,000/QALY. CONCLUSION: PEM-TC can become cost-effective for primary advanced MMRd EC when the cost of pembrolizumab substantially decreases.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim J, Lim J, Lee SW, et al. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis. Gynecol Oncol. 2023. PMID: 37976756. doi:10.1016/j.ygyno.2023.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。